Lecture Notes

**Lecture Coverage:**
- Immunology of Vaccination
- Evaluation of Vaccine Performance

---
#### **Immunology of Vaccination**
- Goal: Mimic Natural Infection without Causing Disease
	- Exploit Specificity & Memory of Adaptive Immunity to provide Immunity without Causing Disease

|    Immunity Mechanism    | Description                                                                                                                      |
| :----------------------: | -------------------------------------------------------------------------------------------------------------------------------- |
|          Memory          | Production of Memory B & T Cells                                                                                                 |
|  Cellular Immunity (T)   | CTL & NK T Cells kill pathogens                                                                                                  |
| <br>Humoral Immunity (B) | B Cells Activated by Helper T Cells → Produce Antibodies<br>- Primary Response: IgM then IgG<br>- Secondary Response: Mainly IgG |


#### **Evaluation of Vaccine Performance**

|                     Criteria                     | Description                                                                                                                             |
| :----------------------------------------------: | --------------------------------------------------------------------------------------------------------------------------------------- |
|                     Efficacy                     | % Reduction in Disease Risk for Vaccinated Individuals in Controlled Trial                                                              |
|                     Duration                     | Antibody Waning (Might necessitate Boosters)                                                                                            |
| <abbr Title="Correlate of Protection">CoP</abbr> | Statistical Relationship between Immunological Measure (e.g. Antibody Level) & Protection<br>- Used in Efficacy Prediction / Comparison |
|                  Herd Immunity                   |                                                                                                                                         |


#### **Type of Vaccines**

|             Type             | Description                                                             | Example                              |
| :--------------------------: | ----------------------------------------------------------------------- | ------------------------------------ |
|          Attenuated          | Weakened Pathogen                                                       | BCG                                  |
|         Inactivated          | Whole Pathogen Killed                                                   | Rabies, Flu Vaccines                 |
|            Toxoid            | Inactivated Bacterial Toxins                                            | Diphtheria, Tetanus                  |
|           Subunit            | Purified Components                                                     | HBsAg, Pertussis Components          |
|     Virus-Like Particle      | Self-Assembled Viral Coat without Genetic Material                      | HPV                                  |
|         Viral Vector         | Harmless Virus that Expresses Target Antigen                            | COVID-19 (Astra-Zeneca / J&J), Ebola |
|    Outer Membrane Vesicle    | Antigen-containing Vesicles from Gram - Bacteria                        | Meningococcal B                      |
|          Conjugate           | Polysaccharide linked to Carrier Protein                                | PCV13/15                             |
| Nucleic Acid<br>(DNA / mRNA) | Contains Code for Antigen to be produced by Host<br>- LNPs for adjuvant | COVID-19 (Pfizer / BioNTech)         |


#### **Application Strategies**
**Vaccine Choice**
- Based on Multiple Factors & Outbreak Situation

|    Factor     |          Description           |
| :-----------: | :----------------------------: |
| Availability  | Stock Amount & Ease of Storage |
|     Cost      |  Cost of Handling & Synthesis  |
| Dose Required |                                |

| Outbreak Situation in COVID-19 |  Description   | <                                                                                     |
| :----------------------------: | :------------: | ------------------------------------------------------------------------------------- |
|   <br>Initial (Wuhan Strain)   |      Goal      | High Antibody Levels → ↓ Infection                                                    |
|               ^                | Vaccine Choice | Balance Efficacy & Side Effects                                                       |
|     <br>Revised (Omicron)      |   Situation    | Omicron evaded neutralization antibodies but not T-Cell <br>→ Breakthrough Infections |
|               ^                |      Goal      | ↓ Severe Infection & Death                                                            |
